SETD4 and prostate cancer: RNAi screens identified SETD4 as one of the methyltransferases whose silencing enhanced the sensitivity of hepatocellular carcinoma cell line HepG2 to sorafenib (39) and affected the viability of the androgen-independent prostate cancer cell line DU145 (40).